// App-Quantinova.ai

: Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.

Researchers

Presenter

  • Eric Raymond

Principal Investigators

  • Richard Hubner

  • Evgeny Gotovkin

  • Lucjan Wyrwicz

  • Eric Van Cutsem

  • Paula Jimenez-Fonseca

  • Roberto Pazo-Cid

  • Jianming Xu

  • Ken Kato

  • Aiyang Tao

  • Lei Wang

  • Yanyan Peng

  • Liyun Li

  • Harry H. Yoon

Medical Centers

  • Ivanovo Regional Oncology Dispensary, Ivanovo, Russia

  • BeiGene (Beijing) Co., Ltd., Beijing, China

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Maria Sklodowska-Curie National Research, Warsaw, Poland

  • BeiGene (Ridgefield) Co., Ltd., Ridgefield Park, NJ

  • Mayo Clinic, Rochester, MN

  • Groupe Hospitalier Paris Saint Joseph, Paris, France

  • University of Leuven, KUL, Leuven, Belgium

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • PLA General Hospital, Beijing, China

  • BeiGene (Shanghai) Co., Ltd., Shanghai, China

  • National Cancer Center Hospital, Tokyo, Japan

Locations

  • United Kingdom

  • Poland

  • United States

  • Belgium

  • Russia

  • China

  • Japan

  • Spain

  • France

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

Biomarkers

  • N/A

Drug/Treatment

  • Tislelizumab

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03783442

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved